BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression

Paclitaxel (PTX) is commonly used to treat urothelial carcinoma (UC) after platinum-based chemotherapy has failed. However, single-agent taxane therapy is not sufficient to inhibit tumor progression and drug resistance in advanced UC. Epithelial-to-mesenchymal transition (EMT) induced by fibroblast...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Se Hyun, Ryu, Haram, Ock, Chan-Young, Suh, Koung Jin, Lee, Ji Yun, Kim, Ji-Won, Lee, Jeong-Ok, Kim, Jin Won, Kim, Yu Jung, Lee, Keun-Wook, Bang, Soo-Mee, Kim, Jee Hyun, Lee, Jong Seok, Ahn, Joong Bae, Kim, Kui-Jin, Rha, Sun Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214101/
https://www.ncbi.nlm.nih.gov/pubmed/30326563
http://dx.doi.org/10.3390/ijms19103164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214101/
https://www.ncbi.nlm.nih.gov/pubmed/30326563
http://dx.doi.org/10.3390/ijms19103164

Ejemplares similares